On July 16, 2025 Imugene Limited (ASX: IMU), a clinical-stage immunooncology company, reported that it will hold a webinar presentation to update shareholders, investors and other interested parties on the latest data from its Phase 1b trial of azer-cel (Press release, Imugene, JUL 15, 2025, https://mcusercontent.com/e38c43331936a9627acb6427c/files/2de571a9-dbf5-1f0e-44f9-d5bfdd998ae5/Azer_cel_new_data_Webinar.pdf [SID1234654386]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will be hosted by Executive Chairman Paul Hopper, CEO & Managing Director Leslie Chong, and Chief Medical Officer Dr John Byon.

The webinar will be held at 11am AEST on Thursday 17 July 2025.

Shareholders, investors and interested parties can register to attend the webinar at the following link: View Source

Shareholders are encouraged to submit questions for the webinar in advance via email at: [email protected]

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.